IPO Corner: Hannah Joseph Hospital Limited

Hannah Joseph Hospital Limited, a multi-specialty tertiary care hospital in Madurai with a focus on Neurosciences and Trauma, proposes to open its Initial Public Offering on January 22, 2026, aiming to raise ₹ ₹ 42.00 Crore by fresh issue of 60,00,000 equity shares, to be listed on the BSE SME platform. The issue size is 60,00,000 equity shares at a face value of ₹ 10 each with a price

• Issue Opens: January 22, 2026
• Issue Closes: January 27, 2026
• Face Value: ₹ 10 per share
• Price band: Rs 67 to Rs 70
• Minimum Bid: 2000 Equity Shares
• Listing: BSE SME

The net proceeds from the IPO will be utilized to fund capital expenditures for establishing the Radiation Oncology Centre and for General Corporate Purposes. The anchor portion will open on Wednesday, January 21, 2026, and the issue will open on Thursday, January 22, 2026, and will close on Tuesday, January 27, 2026.

The proposed IPO is expected to support the Company’s planned capacity and service expansion initiatives, enabling it to strengthen its clinical offerings and deliver more integrated, end-to-end care. These initiatives aim to enhance patient convenience and treatment outcomes while broadening the Company’s ability to serve complex medical needs under a single platform. The expansion is also expected to drive incremental inpatient and outpatient volumes and support sustainable growth in revenues over the medium to long term.”

Hannah Joseph Hospital Limited (Hannah Joseph, The Company) is a Madurai-based, Multi-Specialty Neurosciences and trauma center operating a 133-bed tertiary hospital with allied specialties of Cardiac Sciences, Orthopedics, and Oral and Maxillofacial Surgery.

Incorporated in 2011 and transitioned into a public limited company in 2022, the hospital has developed an integrated care model supported by advanced clinical infrastructure, critical care capabilities, and academic training programs.

Led by experienced medical professionals, the Company serves as a regional referral center for complex Neurological, Neurosurgical, and Trauma-related surgeries while maintaining a balanced mix of inpatient and outpatient services.

For the period ended 31st March 2025, the company reported Revenue of ₹ 7,753.13 Lakhs, EBITDA Margin of 26.47% & PAT Margin 9.30%. For the period ended 30th September 2025, the company reported Revenue of ₹ 4,254.52 Lakhs, EBITDA Margin of 27.38% & PAT Margin 12.03%.